XML 14 R2.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2021
Dec. 31, 2020
Current Assets:    
Cash and cash equivalents $ 232,134 $ 383,928
Accounts receivable, net 382,308 331,429
Inventories 241,392 209,873
Other current assets 145,392 137,508
Total current assets 1,001,226 1,062,738
Long-Term Assets:    
Property and equipment, net 550,255 555,167
Operating lease right-of-use assets 104,723 91,171
Goodwill 353,842 243,347
Intangible assets, net 96,757 52,543
Other long-term assets 305,346 289,595
Total long-term assets 1,410,923 1,231,823
TOTAL ASSETS 2,412,149 2,294,561
Current Liabilities:    
Accounts payable 93,016 74,558
Accrued liabilities 392,681 415,648
Current portion of long-term debt 124,982 49,988
Current portion of deferred revenue 41,130 42,567
Total current liabilities 651,809 582,761
Long-Term Liabilities:    
Deferred income tax liabilities 15,469 11,707
Long-term debt, net of current portion 780,079 858,492
Long-term deferred revenue, net of current portion 43,196 46,163
Long-term operating lease liabilities 88,330 77,039
Other long-term liabilities 85,043 85,604
Total long-term liabilities 1,012,117 1,079,005
Total liabilities 1,663,926 1,661,766
Commitments and Contingencies (Note 15)
Stockholders’ Equity:    
Common stock, $0.10 par value: Authorized: 120,000 shares; Issued:106,748 shares in 2021 and 106,457 shares in 2020; Outstanding: 85,096 shares in 2021 and 85,449 shares in 2020 10,675 10,646
Additional paid-in capital 1,339,413 1,294,849
Deferred stock units: Outstanding: 90 units in 2021 and 87 units in 2020 5,630 4,503
Retained earnings 2,582,434 2,175,595
Accumulated other comprehensive loss (48,391) (53,615)
Treasury stock, at cost: 21,653 shares in 2021 and 21,008 shares in 2020 (3,142,301) (2,799,890)
Total IDEXX Laboratories, Inc. stockholders’ equity 747,460 632,088
Noncontrolling interest 763 707
Total stockholders’ equity 748,223 632,795
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 2,412,149 $ 2,294,561